Pharma reputation slips among patient advocacy groups, according to annual survey
Patient advocacy groups’ perception of pharma companies fell for the first time since beginning a steady rise five years ago, a sign that the industry may not be able to fully hang on to the improved reputation it’s enjoyed over the last several years, according to a new survey.
The survey from PatientView assessed patient groups’ opinions across 10 different issues, including integrity, transparency, equitable access, patient centricity and high-quality products, and assigned a percentage score.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
